Innoviva (INVA) vs Nuvation Bio (NUVB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Innoviva (INVA) has outperformed Nuvation Bio (NUVB) over the past year, losing 12.2% versus a loss of 45.6%. Over five years, INVA leads with a +8.8% price change compared with -53.5% for NUVB. Nuvation Bio is the larger company by market cap ($1.34 billion vs $1.31 billion), about 1.0 times the size.
Innoviva converts more of its revenue into profit, with a net margin of 65.9% versus -325.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INVA | NUVB |
|---|---|---|
| Share price | $18.41 | $3.80 |
| Market cap | $1.31B | $1.34B |
| 1-day change | 0.00% | -0.26% |
| YTD return | -7.90% | -57.59% |
| 1-year return | -12.17% | -45.64% |
| 5-year return | +8.81% | -53.49% |
| P/E ratio (TTM) | 7.83 | — |
| Forward P/E | 8.33 | — |
| EPS (TTM) | $2.35 | $-0.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $411.33M | $62.90M |
| Revenue growth (YoY) | +14.67% | +698.96% |
| Net income (latest FY) | $271.17M | $-204.63M |
| Gross margin | 74.80% | — |
| Operating margin | 39.81% | -338.72% |
| Net margin | 65.92% | -325.31% |
| 52-week high | $25.15 | $9.75 |
| 52-week low | $18.19 | $3.71 |
| Distance from 52-week high | -26.80% | -61.03% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +89.03% | +227.63% |
| Average volume | 865.66K | 5.24M |
| Shares outstanding | 71.08M | 352.02M |
| Employees | 159 | 310 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INVA has outperformed NUVB by 33.5 percentage points over the past year.
- Innoviva is more profitable, keeping 65.9 cents of every revenue dollar as net income versus -325.3 cents for Nuvation Bio.
- Nuvation Bio grew revenue faster in its latest fiscal year (+698.96% vs +14.67%).
About Innoviva
INVA stock →Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 159 employees
About Nuvation Bio
NUVB stock →Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 310 employees
INVA vs NUVB FAQ
Which is bigger, Innoviva or Nuvation Bio?
Nuvation Bio (NUVB) is larger, with a market capitalization of $1.34B compared with $1.31B for Innoviva (INVA).
Which stock has performed better over the past year, INVA or NUVB?
INVA returned -12.17% over the past 12 months, compared with -45.64% for NUVB (price return, excluding dividends). Past performance does not predict future results.
Are Innoviva and Nuvation Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.